About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« I'll See Your Conflicts, and Raise You? | Main | Chronic Fatigue - Retroviruses to Blame, or Not? »

October 12, 2009

Day Off

Email This Entry

Posted by Derek

I'm taking the day off today (it's a school holiday, so I'll be out doing fall-ish stuff with the family rather than pushing back the boundaries of human knowledge. The frontiers of science will come under fresh assault tomorrow, though (as will the frontiers of science blogging).

I did want to mention, though, that Pharmalot is active again - Ed Silverman has his old domain, and is posting as time allows from his day job over at Elsevier. Welcome back!

Comments (2) + TrackBacks (0) | Category: Blog Housekeeping


1. Jose on October 12, 2009 2:07 PM writes...

"So on one hand we have an unproductive big pharma which is cash rich, and on the other a cash-poor university system that has produced fistfuls of Nobel prizewinners. The way forward is obvious: inject the money into university research. Experience tells us this can have major benefits."

The author is also a founder of Ark Therapeutics, a "gene medicine" company!

Permalink to Comment

2. Hap on October 12, 2009 4:03 PM writes...

1) Where's the part about actually making drugs? For example, I don't think Prof. Corey is selling "Nobel 90" as a treatment for cancer and Alzheimer's. The processes to earn a Nobel and actually make effective drugs are...different.

2) Drug companies have already been using the Nobel winners (among many others) as consultants - so their ideas have already been part of the drug companies' successes and the paucity of success recently.

3) I don't think people are going to work at grad student and postdoc wages for what would be, effectively for-profit businesses. Since the efficiency of academics depends part on cheap labor, that advantage would likely diminish. Oh, and where do the students go when they're done? If we're already creating more people with skills than jobs they can occupy now, what happens when schools have a stronger financial incentive to get students, even if they lack the incentive to educate them and there doesn't exist a job market for them to enter?

4) What experience is he speaking of? I'm sure pharma companies don't need any training on how to burn through lots of investor cash and get nothing in return.

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry